Solid Tumor Study Investigating Ibrutinib in Combination with Anti-PD-L1 Antibody Commences in Patients

By: via Benzinga
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.